CANQURA AB (Sweden) is dedicated to the treatment of cancer. The company and its subsidiaries own all rights and patents for the use of novel ISCOM G2 and G3 Nanoparticulate Technology in the treatment of Cancer. This proven and safe technology (used in the vaccine field) has the potential for treating a wide range of cancers particularly AML (leukaemia), prostate and renal carcinoma.
Research to date suggests we have found the way to drastically reduce side effects and induce immune-based recovery.
WE ARE NOW ACTIVELY seeking CRO or Clinical partners and Investors to build on our current successes in research to the next level.
See more under Company Strategy